13F Portfolios

Caligan Partners LP: REVOLUTION MEDICINES INC (RVMD): Quarterly 13F Position History

As of Q1 2026, Caligan Partners LP reported 1,652,808 shares of REVOLUTION MEDICINES INC (RVMD), worth $160.7M and representing 11.4% of its 13F equity book. Quarter-over-quarter share count change: + 368,908 (+28.7%) . The position first appeared in Q1 2025 and has been disclosed across 5 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 5 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 1,652,808 +368,908 +28.7% $160.7M 11.4% $97.3
Q4 2025 1,283,900 +219,651 +20.6% $102.3M 9.4% $79.7
Q3 2025 1,064,249 +427,414 +67.1% $49.7M 6.9% $46.7
Q2 2025 636,835 +171,835 +37.0% $23.4M 4.5% $36.8
Q1 2025 465,000 $16.4M 3.4% $35.4

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Caligan Partners LP first disclose a RVMD position in 13F-HR filings?

Caligan Partners LP first reported REVOLUTION MEDICINES INC (RVMD) on its 13F-HR filing for the period ending 2025-03-31 (Q1 2025). The position has appeared on 5 reported quarters within Pactolio's tracked window.

What was Caligan Partners LP's most recent quarter-over-quarter share-count change in RVMD?

Between Q4 2025 and Q1 2026, Caligan Partners LP added 368,908 shares of RVMD (+28.7%), bringing the total reported position to 1,652,808 shares at a market value of $160.7M.

Does the implied price-per-share represent Caligan Partners LP's cost basis in RVMD?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.